Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17500 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Midori Narasaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Paget Disease, Extramammary, Docetaxel, Programmed Cell Death 1 Receptor, Skin Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Extramammary Paget's disease (EMPD) is a rare skin cancer with no standard treatment for advanced‐stage disease. Although docetaxel‐based chemotherapy is common, no standard treatment exists. Pembrolizumab is approved for solid tumors with a high tumor mutation burden (TMB) and/or high microsatellite instability, and nivolumab was approved in Japan in February 2024 for unresectable advanced or recurrent epithelial skin malignancies. However, there is a lack of real‐world data regarding the efficacy of anti‐programmed cell death protein 1 (PD‐1) therapy for EMPD. We present the case details of three EMPD patients treated with anti‐PD‐1 therapy after docetaxel treatment, with TMB values of 17.8, 14.3, and 5.0 mut/Mb, respectively, and we review similar reported cases. Even in the cases with a high TMB, the response to anti‐PD‐1 therapy was not sufficient. Most cases involve second‐line or later treatments, so further research is needed to determine the precise effectiveness of anti‐PD‐1 therapy as a first‐line treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
ORCID-Profile: Junji Kato, Sayuri Sato, Tokimasa Hida, Kohei Horimoto, Hisashi Uhara
Zitieren
APA
Narasaki, M., Kato, J., Sato, S., Hida, T., Horimoto, K., Matsui, Y., Shigyo, N., & Uhara, H. (2025). Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17500
Vancouver
Narasaki M, Kato J, Sato S, Hida T, Horimoto K, Matsui Y, et al. Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17500
BibTeX
@article{Narasaki2025,
author = {Narasaki, Midori and Kato, Junji and Sato, Sayuri and Hida, Tokimasa and Horimoto, Kohei and Matsui, Yoshiyuki and Shigyo, Nobuaki and Uhara, Hisashi},
title = {Extramammary Paget's disease treated with of anti‐programmed cell death protein 1 therapy after docetaxel therapy failure},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17500}
}
EUVIMED